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CASE REPORT
Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in
patient during pregnancy
Farzan Kianersia, Heshmatollah Ghanbaria, Zahra Naderi Benib and Afsaneh Naderi Benia
aIsfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; bDepartment of Radiation Oncology, Shahrekord
University of Medical Sciences, Shahrekord, Iran
ABSTRACT
Purpose: To report the clinical course of a woman treated with intravitreal bevacizumab dur-
ing pregnancy.
Case report: A 27-year-old female with poorly controlled diabetes and a history of two previous mis-
carriage was referred to our hospital with sudden deterioration in visual acuity (VA) in her right eye.
Ocular findings revealed severe Proliferative Diabetic Retinopathy (PDR) complicated with preretinal
hemorrhages in her right eye, and after maximal Panretinal Photocoagulation (PRP) bilaterally, she was
treated with intravitreal injection of bevacizumab (IVB) into the right eye. Twenty four hours after the
bevacizumab injection, she reported vaginal bleeding, and ultrasound confirmed a 12-week pregnancy
of which the patient was unaware. The patient suffered from pregnancy loss.
Conclusion: Use of intravitreal anti-VEGF by pregnant woman may only be justified if the potential
benefit outweighs the potential risk to the fetus and only if clearly needed. Intravitreal bevacizumab
during pregnancy in women with a history of miscarriage should be used with caution.
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Intravitreal injection of the anti-vascular endothelial growth
factor (anti-VEGF) agents is currently the first-line treatment
in exudative age-related macular degeneration (AMD)1. It is
also efficacious in many ocular diseases such as diabetic
retinopathy, retinal vein occlusion, and choroidal neovascula-
rization by other causes like high myopia2, and uveitis-associ-
ated cystoid macular edema1.
Therefore, younger patients including women of child-
bearing age and pregnancy receive intravitreal treatment
more frequently. Pregnancy testing is not recommended for
women before injection.
Effects of intravitreal injection of bevacizumab have been
demonstrated on the non-injected fellow eye. It may cross
into systemic circulation and enter the fellow2. Although no
short-term systemic complications following intravitreal anti-
VEGF injection for Retinopathy of prematurity (ROP) have
been reported, the long-term systemic adverse effects on
premature babies are unknown1.
Intravitreal bevacizumab is injected at a much lower con-
centration within the eye, and the systemic exposure of IVB
is much lower than the systemic use of intravenous bevaci-
zumab. We report the clinical course of pregnancy in a
woman treated with a single intravitreal injection of bevaci-
zumab during the first trimester of pregnancy.
Case report
Around September 2016, a 27-year-old female patient began
noticing decreased visual acuity (VA) in both eyes but failed
to seek treatment. On 21 April 2017, she noticed a sudden
deterioration in VA in her right eye. She was diagnosed with
type 1 diabetes at the age of 10 when insulin therapy was
started. However, regular follow-up visits were not main-
tained, and her diabetes was not controlled well. Previously
two pregnancies ended in a miscarriage in the 9th and 12th
week of pregnancy at the age of 23 and 25. She was obese,
with the height of 160 cm and the weight of 96 kg.
The patient’s ocular findings on initial examination were
as follows: VA: right eye ¼ 20/200; left eye ¼ 20/100; intra-
ocular pressure: right eye ¼ 14mm Hg; left eye ¼ 16mm
Hg. Examination of the anterior eye segment showed neo-
vascularization of iris in the right eye, and examination of
the optic media showed mild bilateral cataracts.
Funduscopy showed PDR in both eyes. It also demonstrated
extensive fundal hemorrhages and deposit of hard exudates
in the central fovea of the right eye. Extensive preretinal
hemorrhages and areas of nonperfused retina were also
observed in the right eye. The left eye showed extensive
nonperfused areas of the retina with neovascularization.
After maximal PRP bilaterally, she was treated with 1.25mg/
0.05mL intravitreal bevacizumab injection into the right
eye. Twenty four hours after the bevacizumab injection, she
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reported vaginal bleeding, and ultrasound confirmed a 12-
week pregnancy of which the patient was unaware. The
patient suffered from pregnancy loss. Her subsequent preg-
nancy was complicated by hypertension, and fetal death
occurred at 24weeks gestation. The approval of our institu-
tion (Isfahan university of medical sciences) was obtained
with ethical committee number: IR.MUI.MED.REC.1399.365
approval date: 2020-08-03.
Discussion
Bevacizumab (Avastin; Genentech, South San Francisco, CA),
a full-length humanized monoclonal antibody targeting vas-
cular endothelial growth factor (VEGF), was approved by the
U.S. Food and Drug Administration as a systemic treatment
for metastatic colon or rectum carcinoma; unresectable,
locally advanced, recurrent or metastatic nonsquamous non-
small-cell lung cancer; glioblastoma; metastatic breast cancer;
and metastatic renal cell carcinoma1.
Adverse effects such as gastrointestinal perforation,
impaired wound healing, hemorrhage in multiple organ sys-
tems, gastrointestinal fistula formation, arterial thrombo-
embolic events, and hypertension use were reported in
systemic administration1.
The use of anti-VEGF agents during pregnancy and their
safety remain questionable, since the antiangiogenic effect
may have harmful effects on the placenta and developing
fetus, especially in the early stages of pregnancy.
The use of bevacizumab during pregnancy (through trans-
placental transmission from mother to baby) may have the
potential to cause harm to the baby.
There are no human studies on pregnant women to
evaluate the safety of bevacizumab. Incorporation of Fc
region in full-length bevacizumab antibody and binding with
IgG may cross the placenta2.
Bevacizumab has been demonstrated to be embryotoxic,
and teratogenic in rabbits following intravenous administra-
tion. Additionally, it results in reduction in the fetal and
maternal weight, it increases the number of resorbed
fetuses, and increases the incidence of fetal skeletal
abnormalities3.
Furthermore, it is important to emphasize that spontan-
eous abortion is a surprisingly common occurrence. Ten to
twenty percent of clinically recognized pregnancies end in
miscarriage and 30 to 40 percent of all conceptions end in
miscarriage4.
Polizzi et al.5 and Sarmad and Lip6 in their studies have
provided promising information on the fetal and maternal
security profile of intravitreal hostile to VEGF agents in preg-
nant patients. There have been 4 described cases of abortion
following IVB treatment2,7,8.
Petrou et al.7 described spontaneous miscarriage 7 and
10days following administration of IVB at approximately 4
and 3weeks of gestation. Spontaneous abortions occurred
after a short time following intravitreal injection, and poten-
tial risk factors for miscarriage were lacking in these cases;
therefore, relationship of intravitreal bevacizumab to
increased risk of early loss of pregnancy is possible.
However, since the baseline rate of miscarriage is high, it is
unclear whether these 2 events were directly associated
with IVB.
GoMez Ledesma et al.8 described spontaneous abortion
7weeks following single IVB in a 41-old-woman.
Spontaneous abortion rate increases remarkably after
40 years, reaching 41%9.
Miscarriage rates more substantially increase after the age
of 35, and it was impossible to determine the exact time of
IVB use before or after beginning of pregnancy in this case.
Therefore, it remains difficult to clearly establish a correlation
between miscarriage and anti-VEGF.
We reported2 a case of spontaneous abortion after a
single IVB in a 29-year-old woman. The miscarriage
occurred about 18 h after the injection. Whether these
reported abortions are IVB related or due primarily to a
higher baseline rate of fetal loss at an advanced maternal
age is uncertain8.
In 3 patients, a short period between the intravitreal injec-
tion and spontaneous abortions as well as absence of risk
factors for a pregnancy loss propose an etiological correl-
ation between bevacizumab injection and early loss
of pregnancy.
In our case, it is more difficult to establish a correlation
between miscarriage and anti- VEGF, since the patient has a
history of two miscarriage and her subsequent pregnancy
complicated by intrauterine fetal death by hypertension.
At present, anti-VEGFs have been used only in case
reports or small case series during pregnancy. There are no
prospective studies evaluating the effects of intravitreal anti-
VEGF in pregnant women. Probably, information on human
gestational drug exposure will not be derived from observa-
tional studies not controlled clinical trials. Some patients
develop a panic attack just before or during the injection
and blood pressure or heart rate may become problematic.
Hence injecting potentially pregnant women should be
reserved to: (1) pregnancy test negative (2) check vital sign
before the injection (3) monitor the vital sign during the
injection (4) assess the anxiety level vis-a-vis fears of injection
(5) decrease the dose of the injection for several reasons
FIRST the regular dose causes ocular hypertension and ocular
pain SECOND the regular dose is 5 times what is needed
THIRD less dose in the eye the lower the level in body
FOURTH the lower dose cause less reflux or leak and less
entry into the systemic circulation
In conclusion, intravitreal anti- VEGF can be used during
pregnancy if the clinical benefit to the woman justifies the
potential risk to the fetus, and checking the pregnancy status
before injection is necessary and caution should be taken
when anti-VEGF agents are used during pregnancy in women
with a history of miscarriage.
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